Maxim Pharmaceuticals, Inc.
8899 University Center Lane, Suite 400
San Diego
California
92122-1013
United States
Tel: 858-453-4040
Fax: 858-453-5005
Website: http://www.maxim.com/
Email: investorrelations@maxim.com
14 articles about Maxim Pharmaceuticals, Inc.
-
Immune Pharma Announces Formation Of Management Team For Maxim Pharmaceuticals, Inc., Its Pain And Neurology Subsidiary
10/17/2016
-
Immune Pharma Signs Agreement To Fund Maxim Pharmaceuticals, Inc., Its Pain And Neurology Subsidiary
9/16/2016
-
EpiCept Corporation Resolves All Remaining Litigation Against Maxim Pharmaceuticals, Inc.
10/5/2006
-
EpiCept Corporation Settles Maxim Pharmaceuticals, Inc. Securities Litigation
3/26/2006
-
EpiCept Corporation To Update Unaudited Pro Forma Financial Statements Of Merger With Maxim Pharmaceuticals, Inc.
3/24/2006
-
EpiCept Corporation Completes Merger With Maxim Pharmaceuticals, Inc.
1/5/2006
-
EpiCept Corporation Completes Merger With Maxim Pharmaceuticals, Inc.
1/5/2006
-
EpiCept Corporation And Maxim Pharmaceuticals, Inc. Announce Trading And Listing Mechanics Upon Closing Of The Merger
12/28/2005
-
Stockholders Of Maxim Pharmaceuticals, Inc. Approve Merger Proposal
12/21/2005
-
Maxim Pharmaceuticals, Inc. Reports Fiscal 2005 Financial Results
12/14/2005
-
Goodkind Labaton Asks Maxim Pharmaceuticals Former Employees or Testers of Ceplene to Come Forward
1/27/2005
-
Biotech 2005: New Drugs Hold The Key
12/29/2004
-
Centient Investor Release: Biggest Biotech Winners And Losers During Q3
10/13/2004
-
Maxim's Electronic Ceplene Application Is Europe's First
11/12/2003